Research programme: DNA-based recombinant proteins - GeneOne Life Science

Drug Profile

Research programme: DNA-based recombinant proteins - GeneOne Life Science

Alternative Names: Adiponectin; Factor VIII; FNDC5

Latest Information Update: 04 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GeneOne Life Science
  • Developer GeneOne Life Science; Yonsei University Health System
  • Class DNA; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Haemophilia; Metabolic disorders; Obesity

Most Recent Events

  • 24 Feb 2016 Preclinical trials in Cancer in South Korea (Parenteral) (GeneOne Life Science pipeline, February 2016)
  • 24 Feb 2016 Preclinical trials in Haemophilia in South Korea (Parenteral) (GeneOne Life Science pipeline, February 2016)
  • 24 Feb 2016 Preclinical trials in Metabolic disorders in South Korea (Parenteral) (GeneOne Life Science pipeline, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top